SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is trending as a high-volatility short squeeze play, with traders closely monitoring its exceptionally low float and rising borrow rates that are forcing shorts to cover positions. The community is actively debating the stock's potential to reach triple-digit prices, while balancing excitement for parabolic gains against warnings of impending dilution and the risks of a sharp reversal.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh strong earnings beats and positive long-term product milestones against concerns over shareholder dilution and a large executive compensation package. The community is sharply divided between bulls focusing on the production ramp of the R2 SUV and bears warning about ongoing cash burn and the potential for capital raises.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is actively discussing a potential turnaround and rotation back into the MULN crypto token, with community members coordinating to revive momentum despite significant skepticism from traders who draw parallels between these crypto movements and past controversies involving the underlying company.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox stock is facing significant volatility following a sharp post-earnings sell-off, with investors expressing intense polarization over the company's growth deceleration, mounting regulatory and child-safety concerns, and the long-term viability of its engagement metrics. While some community members see the depressed valuation as a deep-value buying opportunity for a long-term recovery, others are actively shorting the stock, citing management's guidance cuts and persistent structural challenges as signs of a weakening platform.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its identity as a global cannabis culture project on the Solana blockchain, emphasizing long-term growth and cultural alignment over short-term speculation. Participants are actively discussing its potential for dispensary utility and long-term ecosystem development while preparing for upcoming culture-focused events.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors react to a powerful earnings report that showcased record cloud revenue growth and robust AI integration, driving shares to all-time highs. The market is currently fixated on whether the company's aggressive AI infrastructure spending will continue to translate into sustainable, high-margin revenue growth compared to its mega-cap peers.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following a significant earnings beat and positive guidance, which has fueled a sharp post-market rally and helped catalyze a broader recovery in sentiment for the enterprise software sector. The community is actively debating whether this performance marks a sustainable turnaround for SaaS companies or a temporary relief rally amid ongoing concerns about AI-driven disruption.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom is trending as investors react to preliminary fourth-quarter revenue results that exceeded expectations and signaled a potential recovery from recent growth concerns. While the stock initially surged following the guidance, the community remains divided, with active debates centered on whether this rally marks a sustainable turnaround or an opportunity to play volatility amidst lingering skepticism regarding the company's long-term management and market competition.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing significant social media buzz driven by a blowout earnings report that shattered analyst expectations for revenue and user growth. Community discussion is heavily focused on the stock's potential for a short squeeze, with many users highlighting strong monetization trends and the platform's unique value in the AI data licensing space.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently trending as investors weigh an impressive earnings beat against concerns over a significant increase in capital expenditure projected for AI infrastructure. The community remains deeply divided, with many traders viewing the stock's sharp decline as a buying opportunity for a long-term leader, while others express frustration over the company's aggressive spending and potential impact on near-term profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

<ul class="summary-bullets"><li>The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy.</li><li>The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial.</li><li>Previously, MannKind filed a supplemental FDA application to expand Afrezza’s use to patients aged four to 17, with a decision anticipated by May 29, 2026.</li></ul>Shares of MannKind Corp. (MNKD) gained more than 7% in pre-market trading on Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing information for Afrezza, its inhaled mealtime insulin used to improve glycemic control in adult patients with diabetes mellitus.The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy. The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial, which showed significantly improved post-meal glucose control after conversion to Afrezza, as recommended by the new dosing recommendations.“We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulin—whether injections or insulin pumps. We believe this refinement to the label helps support appropriate initiation of therapy while reinforcing Afrezza’s established clinical profile,” said Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind Corporation.&nbsp;<h2 class="st-heading-2">Q3 Revenue Boosted By Afrezza Sales</h2>In November, the company posted a 17% increase in third-quarter (Q3) total revenue to $82.13 million, driven by strong growth in sales of its Afrezza inhaled insulin. Afrezza revenue climbed 23% to $18.5 million, supported by higher pricing and rising demand, while royalty income rose to $33.3 million.MannKind also submitted a supplemental application to the FDA seeking approval of Afrezza for patients aged four to 17. A regulatory decision is expected by May 29, 2026.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes. MNKD was among the top trending tickers at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MNKD_jpg_fd37ecdc2d.webp" alt="MNKD.jpg" width="930" height="85"><figcaption>MNKD's Sentiment Meter and Message Volumes at Premarket on Jan. 26, 2026 | Source: Stocktwits</figcaption></figure>Meanwhile, one user didn’t see the FDA update as a major catalyst.<stembedurl>https://stocktwits.com/firefox2778/message/642859216</stembedurl>The stock has declined around 4.7% year-to-date and over 10.5% in the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ag-asml-hl-stocks-soar-silver-prices-record-high-110/cmy78kuR4WC">AG, ASM, HL Stocks Soar Pre-Market As Silver Blasts Past $110</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

Why Did MNKD Stock Jump Over 7% In Pre-Market Today?

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza

Equity

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



2 ETFs to Watch for Outsized Volume on Biotechnology Stocks 

Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.  

<ul class="summary-bullets"><li>Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand.&nbsp;</li><li>Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.&nbsp;</li><li>MannKind’s adjusted earnings per share came in at $0.07, above an analyst estimate of $0.02, according to data from Fiscal AI.&nbsp; &nbsp;</li></ul>Shares of MannKind Corporation (MNKD) rose 8% on Wednesday after the company reported 17% growth in total revenue to $82.13 million, thanks to significant growth in its Afrezza inhaled insulin sales.Afrezza revenue <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/05/3181424/29517/en/MannKind-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html">rose</a> 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand, while royalties rose to $33.32 million. Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.<h2 class="st-heading-2">Q3 Performance</h2>MannKind’s adjusted earnings per share came in at $0.07, up from $0.06 in the corresponding quarter of 2024, and above an analyst estimate of $0.02, according to data from Fiscal AI.The company ended the quarter with cash, cash equivalents, and investments of $286.3 million, after utilizing approximately $133.2 million and borrowing an additional $250 million to fund the <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">acquisition</a> of scPharmaceuticals, which was completed in October.The acquisition is expected to accelerate MannKind’s revenue growth with the addition of Furoscix to its portfolio. Furoscix is used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD).“The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies,” said Michael Castagna, CEO of MannKind.The company has now submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged four to 17 years. The agency is expected to make a decision on the application by May 29, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAnIAAAA+CAYAAACvK/arAAAQAElEQVR4AeydC1xTV57HfxeC4U0AocTKKlptQW1LtbOW2bZTpnW2uPRjfYwtfGo/vtj6aGeqdnZ22u3Ox2V2Zra0s1sV+1HB1S3WdhQ7y0ftpx3pdhxBWxGtFnwWLWhSUMJDIIFA9vxveCSYkIchBPznc8/NvefxP+d+E378zzn33PiZ+MUEmAATYAJMgAkwASYwLAn4gV9MgAkwASbABJwmwBmZABPwJQLsyPnSp8FtYQJMgAkwASbABJiACwTYkXMBFmcdGgJcKxNgAkyACTABJmCbgFOOXHt7BxoamlFbW49r1+o4MAP+DvB3YEi+A6RBpEWkSbYlzf1Yskm2qQ7WOdZ5/g4M6+/AkOiTp74zpEGkRaRJziiaQ0eOjOl0TVAoFIiMDIdaPRpjxsRwYAb8HeDvgFe/A6Q9pEGkRaRJpE3OiJwzecgW2STbVAfVxTrHOs/fAf4OePs7QNpDGkRaRJpE2uRIw/wGynDjRqOcHBsbhdDQIAQEKCBJkhzHOybABJiANwlIkiRrEGkRaRLV3aNRdOxu6LFBNsm2WzrnbuVcjgkwASZgQUCSXNc5u44ceYH+/n5QqcLYebOAzIdMgAkMPQFJkmRtIo0irXK3RVSWbLDOuUuQyzEBJjBYBCTJOZ2z6cjRvKzB0I6IiNDBah/bvT0CXJoJMAFBgDSKtIo0S5y6tFEZKks2XCrImZkAE2ACXiRAGkVaRZplq1qbjlxrqx4hIcE8EmeLGMcxASbgMwQkSZK1ijTL1UZRGdY5V6lx/uFLgFs+XAlI0sA6Z9ORI69PqQwYrtfM7WYCTOAOIkBaRZrl6iVTGSrrajnOzwSYABPwNgHSKtIsW/XadOSMxk4oFP628nMcE2ACTMApAt7KRFpFmuVqfVSGyrpajvMzASbABLxNgLSKNMtWvTYdOcooSbw6lThwYAJMwLcJSJL7WiVJ7pf1bSrcOibABEYSAUmyr1V2HbnhB4BbzASYABNgAkyACTCBO4sAO3J31ufNV8sEmAATYAI9BPidCYwAAsPDkWvSQtM0AmjzJTABJsAEfJ5ADUr2HUW1z7eTG8gEmAAR8Jwj16VFye6t2LCBwmbk7zuN+i6qwo1QdxQF+8/3Frx4eB/2HL7Uez5YB2f3f4iSusGyznaZABjBMCdQe+RD5G79FGctte3KF8h/zze1w3iqCLlFFVbUG4/twY7PtVZx1ic6XLusRb11JJ8xASbgowQ85shp/u9TnFHNwssvLxchC08lBUPprvV6HerbDL3I7pm9Ai/Pnth7PjgHTai/YYDeODjW2SoT8HUCJhPQJv7umptbodM14/r1BtCPN2u1N6DR1IlwHd9/fwN1dTrQz1o1Nt7EzZttsLck3tev1532dRoMUJhqcOZ0X+mzX1+BHgaf1A7FZDUiLl/B2d7mNuGbczrEJsT1xvABE7iTCJiE0N24UY+rVzW4ePEyKirO4dSpb1BW9jWOHTuBL78sx4kTp/H11xWorLyAqqrvhPZ9j+bmm0OEyXG17rpat1jWt/c5XoA/4u+diJDuXC0Xv8DurVuRm7sV+WKkrYXiadSt6DjO7N+J3I0b8Qfq5baJBIr/7BKMV/+K3O5eLvWCC46Yh8rouOjIaXy8XYz8/ddWFJTUoPrwHuTnChvvFeGUbFzY6dLh1D5h+z1R75Y9KLkq4sRGo27FJ4/I7dkglzf3TCm+TCdEbp/IL9oosvLGBEY8AdOlb9G5LR8dy1+CqbwcjY3NQrBahEOnlx00Wu7e1dUFoX0imNDZ2YWODiPoKeMtLW1oaroJeifHTif+fsgRNFHmEUxOER6O+gunzVfYdR5na8MRG2w+lfctl1C8O1/ol9CSvIM4261JmiN7sEVoYO57+dh9uAbUZ7QVV3/yIHaQXm7cjA07v4CmZ/Tv6lFZt3JJ0+TwoXkGwU59cluCJiMhogZVl+Uz4amfR1XjWCSMF+c9Gkltyt2JospWEdlvIz1+/yhqu6NJfws8pMXdJvmNCQw6AdKspqYWuRNKHU9yzqqrr4nO6g1Zw9ra9ELXOmSNI71rb29Ha2ub0MMm0Xmtw5UrNfK7r+qcxxy5hEcfh/q7IuGQfYzi03WySMmfTv1R7PlUh8SM5Vi5cgl+0P4Fis+JFKMBhsvnUH9/JlauXo2nYy/h2IkmIGYmMh8dC9z9d1j50kKkxADUCzYYOkUh8/HlKwY89qIY+XshCcZjRTgWNgtLVq5GerwWZV+aHb6z+/egLGKWsCHqfVaNC4eOolFYMLTV4eyVSDy9tLt8WbncW71vdjqmhIZjyrMi/+zJIidvTGDkEjCJURrjG/+KjqVZ6Hx/F0wXLsJ0vAxK5SiXL3rUqFGyY9cmRvPImaNRvBbh5I1Yfy52IhJ051BGHc9zQsPuHouojh5sOpTsLUZ94nOy9mTNNKK4mG4TqcCx48DfviT05aUlmD9zLBSwFQco1cmYI/Rp5eoVeCqiAp+WCl1EHYo/qUD0LCq/HLPilYh/cqHQR3v19bQnHFMmBqP6fI0cYTh9CfXjJ+I+cXZ2/26UCe1cuVLYfDEZLYf2oaQeEEl9G+m0GIU0q69Zfz2lxX2V8BETGBwC1BGtr2+SHbibN1uFs2YUWtWBiIhwlysMFx046sD6os75uXw19gqETEZ61gq8+FgM6o9+iA3dI2yGi1fQJAAYz5Wj7MTXMIxSou6qeRQMwWMxKd4f9IoICxEOm40eISX2CyFxQjip5VHhCIEakx4Ml3OEBCkBE0nOFVRd9UdUoEbUKeqtNkJ5U4vLML9ixychoqc8CZU5mvdMYMQTMGm1MGb/OzoWL0PXX49YXW9X2Qm3HDk/+luysESjdjTtSg4diZ5F0gg5VGPqxFZc+KYVZ8/rEJ8oOp49V9Z2SYx4hSOiUzh6J8pxqk2BwFoNNBiPhLt1OLbnC5zRGKAIgHjZigNC7opB5+VyFO8vwsnr5DyRLpKuKaEME8XE5u9vQFO9mAWxW5/I1L1FJI6HsvqSaANw9rt6jJ9MHVXSyBCMfyDOnCtkGh4c14Sqi8KmOcap/e1qsVOVcCYm4CKBzs5O9HQq9Xrr7zQ5Y+44ciEhQVat8CWd6yfBVu1040Q4T/f+EPOXL0FKyHmUnTZAL6ZhrAypp+EH90ZaRXn+xABjh6XVcEyamYx4yyg+9hEC3AyvEBDC1pm3HR2ZL6Lrz8UQcwi3VGu6cAHKTqs/nFvy9I+gp423txv7R8vnPWJK99pRz1iOHCE79YMTYTj/Kc40jsPUcRYXZTD2zUZQtF8cHph5L6IQjAfmi5G4GSGo+nQncvdVwGAzToywvZ+PgxeVmPToLDyeEEJWRIjD3yYrcWrvh/h434f4vHYyUmcoAbv1iSI9W9REoX01qKo/jQva8Zh0LyWQRvojMICO+4Kxw/qfXl+Ku0dUj2VZ1mJLGnzseQLNzS1iGrQe9jqRNM0aFhbqUsVBQYEwGrtslvEFnfOQI9eKs4ePo7rf/wClUomIsWooW42IejAZ0x8SQbxPvVsJhy/bzBwWM2cYhzExrWhR3GuuU653nBBTc6r9vRGdt1WvfcucwgSGioCpugYd/7gSnf9TIIZ3aGTHTku6TJBOnoK/v/OyoBRTsdTDtWNRjm5v75CnNmi6VY4YCbuoJCR01KAl4X6oLa9HNRZjlC0wRgmtI92hkBgHJTpF59IfURNmIP3FmYj97hIu2IyrwTVdHKbPSkJ8uBItYrrabL4Jpyo6MX3eHDzx4zlYsuhxqOljslufuZR5H4fEhE5UFV9Cbbx5WhUYJzRSh6rzreYsXVdQpVFizFjz7IY5UuzvEi7oTR1qZV1sRe31FhHpykb1uKPFrtTBee84AjYumDqLtBCLFmvZSLaKkiTJpdkHGsHzZZ3zs7o6t0+CERumwcH3Nptv8N24A2WjfojUB4TBcalIn6LDwdydKBA9SXmZ/g0RP9A2eTISar/AhvdEz/TcQBntpSkxPX0Wwk/tQO7Oj7FnZz627D+PgfuaQuwmKHCmcCtydx/lpff20HL8sCJgOn0GHS+tgumic4/vcXV6NSAgQPRUB3AOu2nRAgiabm1oaO6OGe5vkXjsuUWYPzOy34WMxVOzk1D/yWbk7ypCQd5WFBzVAXXl2LM9Hzv2UNxRtNz/MKbaisNYJMRo8VnehyjYUYDKtuBu++GIj23BsV1CR0XI3f4hig5fQovIb7M+WL/UE8eipVqDMUJbzSmWGlmA/NxPUT8lDU/Jo4uRiAipQdlhLeA3GVP/RoNiWhDx3j7UhkSZizu9t6zHWS122jhnZAIyAeosXr+uA422yREOdgZDh0v3ydH9ceQoOjArJjpMGAqd85AjBzHilo6sl1dgacZCvPiPK7ByfnLvCJj6hwuxcuVC/AP1JMV7SrTAoX4cS5aKXqU4pE2dughLUrvv1whKwpzVK5C1eAmeFtMAlmmWx8A0zH91DshfvMUG3bO3XNiYl4qnn1+CrPTJolcMMb2xGvN7CvQv/8QivJq1CFnPzextO9nlwASGI4Guzw6h4+drgRbnR1FMLt4nZzLJQzVO42lt1cuPLjENr5UQvddnpT/KcITIU5NxSF26CKk9Q3N3z0TmSyuQ+Q+PY/7i5chMEc5ezAw8l7UEmU8/jjmLluPFJ+IAW3GIxPTnliNrwdOY/0Im0udnmnWx6zxOXh2LObQw4SWR/tOZCDx/BMc0omm26hPRVpvoUGe9ugJzEi1iezUyHZnCbuYPRZvkZOGMLluBRfK5ElOfFXq+aCGWZmUKJ3WhuT0inxWL/lpqqee99aRaabEwwRsTuG0CNIVKt290iRkFZ40ZDO1OO3KSJLk0ekdt8LbO+VGlngzK8B5x62fVT4kIMVUAp1/+Ah5u+6UIsdMee5bFdLDCXhrHM4FhQqDr4/+F8Te/BTo7XWqxqb4egV2diIgIRWRkOEaPViE2Ngpq9Wg50DHFUZpKFSbMu2afGkMiSsv4h6szR9fgTCAtVPZTWFt6ZCvulrKGFjHN2or6BjPvziYNajsjEavqa8ktZfqSBjyi+vu3E37+UFi03V3blhVTPWbH1zKWj5mA+wTodg1a1OCqBVqoEBERhvHj/waTJk3AlCn34sEHp+IHP0jGww8/iAcemIKkpMm4554ETJgwzud1zuJP1VUUnH/QCLBhJnAbBLoOfALjf77rvAV/f/j95CkEbPhPjCr6E6SQYNAKraAgJUaNCgAtaJAkCZIkyccUR2nBwYEIDw9FTEwkQkODXbq3jqZCyJlzvpF3eM6gZMyfNw61XxzAx/uKcPCUQkztpmNq0B3OhS//jiVAo140jekKANIs6ohSx1ShUCAuLgbR0ZEICwtFYKASfn5+Qsf8QYsbwsPDREc2SuhbtM/rnJ8rEDgvE2ACvk3ARM+Hc8GJ83t4BgIKdkDxz/8EadpUwE9y+QIDAhRC6EJw111mwZMk52yQM0cP6QS/nCKguCsZTz+bjjkUn5IT+AAAEABJREFU/n4G4sOdKsaZ7hACd9Jl0v1qrjhxtCjrrruioBKzCNQRdYeVL+scO3LufKJchgn4IoH2dhj/5V8B8e6weeHhULz+Syje+h2kuDiH2Z3NEBoaJKZiI0HC6UwZekgnTbU6k5fzMAEmwAToloz6+kZ5YYEjGjTCFhkZJkbdIuSRNkf5nU33NZ3zc7bhnI8JMAHfJmD8r42gR404aqU0fhwC8rfA76knHWUdIN1+kr+Yqo2OjpCnZ+3n6kvR6ZpB96z0xfARE2ACTMA2ARqJoxE526l9sQqFv5gWjZSnSftiPXfkSzrHjpznPle2xASGjAAtUug6/FeH9UsP3I+A3A2QRo92mPd2M0REhDrlzHV1daGtTX+71XF5JsAERjgB0gq9vt3hVdL0Kd276+8/+C6OL+jc4F+lQ+TOZeBcTIAJ2CfQERqGUbvfh//8eYCf7T9r6f5pCMj5PRAcbN+Qh1MciRzdcBwdrRJNChSjcuYVmR5uAptjAkxghBCgkTi6140WY9m7JHLiaEZAkiR7WTweP9Q6Z1vxPX6ZbJAJMIHBIkAPwaTnKNW1GNCZtQwBO7eDRt4s65NGRyMgez0QEGAZ7ZVjErn+98z5+UnyI05iYlSge+S+/74ejY3OP+/OKw3nSoY7AW7/CCLQo3OkdbRqnh6FRE6b5SXSCFxUVIS8wt4y3hvHQ6lzfh67QH0DtFptb2i46THLNgzpceAVNSLj16HUaCO5N6oY6+LVUK8p7o3hAyYw0gj0/CRNj9A1hITB750cKH6zHtIYNYSqQfHrN4HwMAzVKyoqXH50CdVPvenY2GjRLAm1tfWgBQ90A7Neb3DqVyLIxpCFbp2z1jc9GoT2WccNWQuBy5swW+je7M1VQ9gIrpoJeJZAf52j31SNjAwHaYu/v79cGZ1TJ1E+GYIdtYXuzaOqvalznnPkPlsFtVo4Td0hMkyCFD8PeWfpkgYh6AGxOTCsh6ZGOJfXHed0YIiTmYBjAkOQg6Ya9MIBsqy6rc0gO0gt9z8IxX/nQfEfv4U0dYplFq8fS5IkBDdCXtFKvekbNxrQ0HDrIgdy6rzeOFcq7Na5yGfyoO0tV4xVQvdSfMVxMupRJXSvalA7070XzwdMYNAJDKRzHR2doJH96OgI+bmXg96YASqQpKHROc85ct0XN3enBhqNCKe3Ie16IZattBS87ky3/RaItC0atFXn4BHFbRuzMvDrX/8aP/3pT63i+IQJ+CoBeiimrbbRCBf1WGt1zZBmTLeVxWFcTU0NEhMTERISgrKyMjl/fX09nn/+eXk0TZIkpKSkgPLJiQ521FOlG5VpaqSjw/ZQOjmh1HYHpoY++fPVWFs0PDuIrHFD//XhFrhGwJHO0Y/l959mdVQDaRppmySJQafu8Pvf/14uRhp0/vx5/PznP0dwcDB64uVEBztXdc6BOaeSPe7IBariEBcnwtR5mPuEaENzA9rEG236M5swL74bWkAS1n3eQNGAUYvCNT/GhKDutKCH+tJgnh5dXVSJtx8NEv9AkvD2RaB4jRj9E1Or5knTBpS+mYKg7g/jlpFAYzk2palFWWE/IAVvDzBKSCKXlJTEzpz5k+G9jxOwJ3A9zSZRkSSp59TpdxKynJwcVFdXQ6lU9pZ7//33ce7cORw/fhylpaW4evUqXn75Zej1zjk19FDNXmM2DqhecvZsJPlQVBrS0vXY9Uo2ym37o7DWOjXmbahED6GqzbOhnrUJpUXLoA6QIC06ADnukd+gcN8yJFGc+MySflEK7dE3kBIk8ohz9ZID6FZMoKYQ61In9GpeUPI6FPcmYsAXa9yAeDjRBwkMhs7V1tbCaDTid7/7Hf74xz/K4ZlnnpGvvrW1FW+++SZ27dqFtrYeD0ZOcmrnbZ3zuCNXdbgQhX8sxKY1aVh3UIW5azKRQJfesAvzpq1GcWIODlV9i0OvBeLtVDH1Ks9PVOHEVypkbDkk3rchI64cb6e9gVIqJ+SPpkc3PZOETepsFHxUgMx7AP11LbQ1GpEqMl3Mw9J/K0XKuxViNLAC+19JRYLlM04/yEHhjLexd+cqJBtLsc7BKCELnWDKm88ToF9GoOX4AzU0NDRkoGS7aX/+85+xY8cOLFu2DAaDoTcfOW1fffUVpk+fjpkzZ+JHP/oRTpw4AZ1O15tnoAOlchQciVybzz+KpAopz7+OhMu/wbrtsoBZX3K31hXGrcLer05g/wo1Cl9JwrwPuj2tm1XQfrYaKVkVyHx3Lw79KhWgOOG0zfsFsGpXAVbNACrfSoF6QTlSt+xFzrMqaLcvRc7x7qpqTqBElYG84hM4kZ8B9cm3MftNs2J257DzZo5mjTNz4L3vExgsnSMnjlbNP/nkk5g/f74cEsUMBBGhkbrdu3fj4MGDoBE5inMleFvnPO7IlW5dhVVrViF7cykaFIGi51gFkq+q7Tk4gGSs+/dMJAUGIWnlKqSJ0bbirwAoHkH24b3IXvAQ1IEJSHkkTnhqJSi5LNJ6tpkbUfLRWmQsSIZI7Ym1etdUVkEXmoi011YhVWWR9EIBDq3PwNwXcrAuXcTX9Y0SijObGwudTSwc6UMEHI1c+fv7idE011ep3rhxA6+//jqee+45PPbYY1ZXLElS7xPSqaf6/fffIyEhAWFhzi+koN87xAAvg6FjgFTfSAp8eB2yhZYUv7IWB/rdi2bWuji8vnkj5s5IRtq7eXhdiNaBd/LQt/wgUDhsJchZMRep9wmdlC8rETkHt2HVggxs/FWGHJORux/ZL8zF2sVp4lyLKo14o21mNkoKszE3WY3A8SmQJbO0xMI+ZRo4sMYNzIdTfYPAYOlcR0cHRo0ahe3btyMrKwsffPABKM5TV+1NnfPzVKN77GTQPXLVGmjaTKhYH4nCX2Qi5wxQWV4uspTjjYfVkBdFxC/DAREjb0YtCrOSIAVFQv1oJrL3US9XD1hOW0xKsOvA4Z612LtlLnRbZyMpTIJ6bh4qLcvKldAuECoV+OVFAlzV4BGwd59ZT42OhKQnn+U7TW1u2bIFzc3NIGcuYIDHlRw4cACHDh2SR+1CQ0MtzQx4HBQUOGA6tcFo7Bwwz9AnqpDxTg4S9buwbnOlVXO01eSupSJFjKqZE5KR8pQ4On4CfTkTkBAv4uxtCnsJ3fE1hViWKCEoUo2URdko1Ip4IZlizxsTGFEEBkPnCFB7ezvGjBmDCRMmyLeGZGRk4LXXXnPqp7+ovKPgTZ3zuCNneXGJj6YiUPQRq4SuJU5LFEmPYGO1SQZFYk2hQPRqtdszMW+rHqs+1cGk06BkPeUV2V3YEpfvFc5jGyo+ykDQvmWYvb5PMl0w05uVeqsVFRX46KOPeuP4gAn4EgFHvUca3ne1vTRNmp2dLS9wWL9+PTZs2AAaeaO4kydP9pr78ssvZQdu8eLFWLhwYW+8Mwf0eICAAMWAWR1d24CFvZUoOpB5L6tQ+eZeVN3XV2lcPN1MUo7y3ntxq0RHVqTPeAiuK5sod8umRd6iecjTr8KhOhN01SXInnpLJocRrHEOEXGGoSFgVasjLXBH56gCmnH45ptvsGbNGuTn52PevHkoKioC3TtH6bcbvKlzHnfk9A1aaLVVKD+4CcsWb4IeczH7CSDh2aViYrUUbyx5G8WXKU8lDuwrF+lA202dYBYIdaQe2svFyPvIRSfsbB7WvVUMrT4QiU+kymLZZtQLm+5tLHDuceNS3iNAv03a1WUasEJHzpKtwnSvW3R0tCxmn3zyCWhRA3W4jhw5guvXr8tFKisr5ZWrdG/JW2+9hYABRu3kAjZ2AQ4dOV8fkTNf1CPrNyFNX4rSXqdNaN2CVUgVY285vxIzA1otKreLaVgxK5GcMRfk4plL3s6+DQ3NonyoGpFGMd36eR4KhH0RY73pGqC3OTMBsMZZo+Iz3yQwWDpHV2s09v1x+Pv7Q6lUyosfurq64KmXt3TO445c4SKaOp2Ah9JWY69qKfZeKEAGzbqI3mtx8VqoP1+HHydQniTM/tVelAt/K2FxNpbGVZqnXSethvaRNAw8+WKNuaGhAZXv/BhqMa0qxYgp2/vWouAXydaZnDwbP348KngkzklanG2oCDgSG4XCH5Ikudw8cs6+++479ARa8EA3+9JNv5R28uRJ/OQnP5HtpqWl4bPPPsOePXvk1atypJM7RwLn6PqcrMa5bLeTS5WBjf+RaG1hrNA90rqiZUhSq5G0pBDqVw+h+NUE63xunyVg6ZtLEXfmDTwk7E9YqUVKuoVi3jMXS8W0buVvM+UV/v2rYY3rT4TPfZWAIx1wV+caGxvlJ1Ns3bpVfnzS/v37QbeK0OOUYmJiQI9Z+tOf/gRa9EVTsF9//TXonOJdYeUtnfOcI5deYDVlSr143VfbMPeePoFRPZGDio426DQaaHRtMFVm4xFKVqVhm4bidWIapwLb3t2PNlMF1t5DyNJQYDLBtDONTnpD2k4RZyoAxapmrsV+jQltdZpuuzndix1uLSuXO70W9iT18uXLPJ3aS5kPfJWAI4Hz8/Pcn7Ylgz/84Q/yI0m+/fZbLFmyBAsWLJADTcla5nN07O8/cPscXZ8j+4OWLutcRbc2mWtJeK1C1r6K1/pUxVLrdHS/8DupUMH8Mue3ZcMiTq7HBLr1RC7V71yVvg2aNh00daSj27Dxf8V7r64lYO1XbUJnS7DWYspXtiN2rHECAm/DgoAjHfBzU+font7U1FT87Gc/Q3x8PNLT0zFt2jTQDAOtZK2qqgLdM/fLX/5SHqWjx5DQOcW7As5bOjewmrrSYqfzBkJFz5lTkQcHi1egiFchUAG3X4Gj4xB3i123zQ1WQbbLBG6bQJeDaVU/P9dH42w1igSupaVFftwIpe/YsUN2WqijZhkoH6U7GxwJcJcHpzecbZPn8wUKTYvDoElSoApxowNh+xUo6la5NLMBfjEBHyPQNUg65y+mUlevXi0v6qKV93RLyV/+8heMHTtWJkCPVyLds9Q4Oqd4OYOTO2/p3BA4ck4S4GxMgAnYJUA/czVmTAzshaioCLtlfSGBnsJur+0UP3p0pC80k9vABHyEwJ3ZjMHWOXLoYmNjoVKpBgWwt3SOHblB+fjYKBNgAkyACTABJsAEBp8AO3KDz5hrYALDjgA3mAkwASbABIYHAXbkhsfnxK1kAkyACTABJsAEmMAtBHzEkbulXRzBBJgAE2ACTIAJMAEm4ICAXUeOVms4KMvJTIAJMIEhJ3A7WnU7ZYf8wu/0BvD1M4E7iMBAWmXTkaOH7Bl9/rcO76BPkC+VCTABuwRIq0iz7Gawk0BlqKydZI5mAkyACfgMAdIq0ixbDbLpyNGSWYOhw1Z+jmMCdyoBvm4fJUBaRZrlavOoDJV1tRznZwJMgAl4mwBpFWmWrXptOnLBwYFoaWmVH/xpqxDHMQEmwAR8gQBNN5BWkWa52h4qQ2XJhqtlOT8TYAJMwDEBz+QgjSKtIs2yZdGmI9GMU7oAAAGlSURBVEden1I5Co2NN22V4TgmwASYgE8QII0irSLNcrVBVIbKkg1Xy3J+JsAEmIC3CJBGkVaRZtmq06YjRxlVqjB0dnahoaGZR+YICAcmwAR8hgD1UEmbSKNIq9xtGJUlG2SLbLprx1fKcTuYABMYOQRIk0ibSKNIq+xdmV1HjgpER5t/5qe2th43b7aho8PITh2B4cAEmIDXCZCokQaRFpEmUQN6NIqO3Q09Nsgm2aY6qC537XE5JsAEmIC7BEh7SINIi0iTyE6PRtGxrTCgI0cFyAuMjAyH0WiETtcEjeY6rl2r48AMcO0afw/4b8F73wHSHtIg0iLSJNIm0ihPBLJFNsk21UF18Wfrvc+WWTNr/g6YvwOkPaRBpEWkSaRNjjTOoSNHBmhelozFxkZhzJgYDsyAvwP8HRiS7wBpEGkRaRJpkycD2STbVAfrHOs8fwcG6TvA2ulQO0mDSItIk5zROKccOWcMcR4mwASYABNgAkyACTAB7xJgR867vLk2JsAEvEuAa2MCTIAJjGgC7MiN6I+XL44JMAEmwASYABMYyQT+HwAA///AufZ5AAAABklEQVQDAP9m0tFm55/SAAAAAElFTkSuQmCC" width="624" height="61" alt="MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits"><figcaption>MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Wednesday’s gain in stock price might not last.<stembedurl>https://stocktwits.com/nomalarkey/message/635009498</stembedurl>Another sounded optimistic about the stock’s prospects.<stembedurl>https://stocktwits.com/6Figs/message/635008031</stembedurl>MNKD stock is down 8% this year and approximately 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-executives-including-cfo-rally-for-musk-s-one-trillion-pay-package/cL2qZJZREGA">Tesla Executives Including CFO Rally For Musk’s $1T Pay Package</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.

<ul class="summary-bullets"><li>Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.</li><li>The company said on Tuesday that it met with the U.S. Food and Drug Administration (FDA) but did not come to an agreement on a path forward for the design of a clinical trial in patients with late-stage chronic kidney disease not on dialysis.&nbsp;</li><li>Akebia believes regulatory alignment for such a trial would require a significantly larger number of patients than proposed. &nbsp;</li></ul>Shares of Akebia Therapeutics (AKBA) slumped 24% on Wednesday morning after the company said that it does not expect to pursue a broad label for Vafseo for the treatment of anemia in patients with late-stage chronic kidney disease not on dialysis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-provides-update-vafseo-non-dialysis-patients">said</a> on Tuesday that it met with the U.S. Food and Drug Administration (FDA) but did not come to an agreement on a path forward for the design of a clinical trial for the use of the drug in the said patient population.While the company is yet to receive the final minutes of the meeting with the FDA, Akebia believes regulatory alignment for such a trial would require a significantly larger number of patients than proposed. This, in turn, would require “meaningfully more” time and cost to complete, and the company does not plan to initiate the trial, the company said.<h2 class="st-heading-2">What Did The CEO Say?</h2>CEO John P. Butler said that the company is “disappointed” in the meeting outcome.“We believe our decision not to pursue a broad NDD-CKD label, based on our discussion with the FDA, is in the best interests of our shareholders. We were encouraged by the discussion with FDA on smaller subgroups of CKD patients where we may be able to align on a potential clinical trial design and path forward,” he added.Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. In the second quarter ended June, the company reported Vafseo net product revenue of $13.3 million after nephrologists began prescribing it in January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user expressed optimism for the stock, saying the FDA did not shut the door on the trial in its entirety.<stembedurl>https://stocktwits.com/JonahTheTrader/message/634144578</stembedurl>Another highlighted that the company’s product is already on the market, and it has good financials.<stembedurl>https://stocktwits.com/Popeye989/message/634137009</stembedurl>AKBA stock is up by 23% this year and by 37% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/purple-biotech-shares-soar-on-breakthrough-for-experimental-cancer-drug/cLGZ8OAR3wS">Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion

Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.

CEO John P. Butler said that the company is “disappointed” with the outcome of its meeting with the FDA on a path forward for the design of a clinical trial of Vafseo in patients with late-stage chronic kidney disease not on dialysis.

Several firms increased their price target on Ionis Pharmaceuticals (IONS) on Tuesday after the company announced positive results from a study of its Zilganersen drug in children and adults living with a rare neurological condition called Alexander disease (AxD).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-pivotal-study">announced</a> on Tuesday that in the study, Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization of the primary endpoint, gait speed, at week 61 compared to the control arm, with a favorable safety and tolerability profile. The company also said that Zilganersen indicated evidence of slowed disease progression, stabilization, or improvement.The firm intends to submit a new drug application to the U.S. Food and Drug Administration in the first quarter (Q1) of 2026. According to Ionis, Alexander Disease affects approximately one in one to three million people worldwide and has no approved disease-modifying treatments. The disease is characterized by progressive neurological deterioration, resulting in loss of functional mobility, independence, and the inability to control muscles for large movements, swallowing, and airway protection.Guggenheim on Tuesday raised its price target on the stock to $92 from $90, while maintaining a ‘Buy’ rating on the shares, according to TheFly. The new price target implies an upside of about 50% from the stock’s closing price on Monday.Other firms also hiked their price targets:<ol><li>Bank of America hiked its price target on IONS to $83 from $81 with a ‘Buy’ rating, while terming the news “an incremental positive” as Ionis could add another product to its expanding commercial portfolio.&nbsp;</li><li>Morgan Stanley hiked its price target on IONS to $86 from $71 while keeping an ‘Overweight’ rating on the shares.</li><li>Barclays also raised its price target on IONS to $80 from $78, with an ‘Overweight’ rating. The study results create a high probability of FDA approval, the analyst said.</li></ol>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IONS">IONS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:574/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_11_39_52_AM_png_6ae39ea7d7.webp" alt="IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="574" height="63"><figcaption>IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>IONS' stock is up 80% this year and approximately 50% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-ford-bronco-vehicles-after-recent-recall/chDhCRLR35q">US Regulator Closes Probe Into Ford Bronco Vehicles – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares. 

PBE
Invesco Dynamic Biotechnology & Genome ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PBE News

PBEInvesco Dynamic Biotechnology & Genome ETF